Literature DB >> 27863138

Prevention of sinonasal inflammation by a synthetic glycosaminoglycan.

Abigail Pulsipher1,2, Xuan Qin1, Andrew J Thomas1, Glenn D Prestwich3,2, Siam Oottamasathien3,4, Jeremiah A Alt1,3.   

Abstract

BACKGROUND: Glycosaminoglycans (GAGs) are polysaccharides that are distributed on respiratory epithelial cells, endothelial cells, and submucosal glands. Uniquely positioned, certain GAGs exhibit anti-inflammatory properties in respiratory diseases and serve important roles in repairing mucosal surfaces and modulating mucociliary clearance. We hypothesized that topical administration of a synthetic GAG (GM-0111) would prevent sinonasal inflammation in a mouse model of rhinosinusitis (RS).
METHODS: To test our hypothesis, C57BL/6 mice were intranasally administered fluorescent GM-0111, and sinonasal tissues were examined for coating and penetration ability. To test therapeutic feasibility, mice (n = 6) were given GM-0111 or hyaluronic acid (HA; 800 μg dose) prior to inducing RS with inflammatory molecule LL-37 (115 μg dose). After 24 hours, sinonasal tissues were harvested for histological and biochemical analysis of inflammatory markers (inflammatory cell infiltration, lamina propria [LP] thickening, and neutrophil enzyme myeloperoxidase [MPO]) and cell death.
RESULTS: GM-0111 was observed within sinonasal tissues 1 hour and 24 hours after intranasal administration, indicating rapid and effective coating and penetration. GM-0111 prevented sinonasal tissues from developing inflammatory changes, with significant reductions in mast cell infiltration (p < 0.05), LP thickening (p < 0.001), and MPO levels (p < 0.01) when compared to tissues treated with LL-37 and those pretreated with HA. GM-0111 reduced cell death within sinonasal tissues in contrast to LL-37-treated tissues.
CONCLUSION: We report a new synthetic GAG (GM-0111) that uniformly coats and penetrates into the sinonasal mucosa to prevent sinonasal inflammation and cell death in a mouse model of RS.
© 2016 ARS-AAOA, LLC.

Entities:  

Keywords:  anti-inflammatory therapeutic; cathelicidin; immune response; rhinosinusitis; sulfated glycosaminoglycan

Mesh:

Substances:

Year:  2016        PMID: 27863138      PMCID: PMC5299046          DOI: 10.1002/alr.21865

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  60 in total

Review 1.  Hyaluronan and homeostasis: a balancing act.

Authors:  Markku I Tammi; Anthony J Day; Eva A Turley
Journal:  J Biol Chem       Date:  2001-11-20       Impact factor: 5.157

2.  Apoptosis of airway epithelial cells: human serum sensitive induction by the cathelicidin LL-37.

Authors:  Y Elaine Lau; Dawn M E Bowdish; Celine Cosseau; Robert E W Hancock; Donald J Davidson
Journal:  Am J Respir Cell Mol Biol       Date:  2005-12-09       Impact factor: 6.914

Review 3.  Regulation of protein function by glycosaminoglycans--as exemplified by chemokines.

Authors:  T M Handel; Z Johnson; S E Crown; E K Lau; A E Proudfoot
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

Review 4.  The association between allergy and chronic rhinosinusitis with and without nasal polyps: an evidence-based review with recommendations.

Authors:  Kevin F Wilson; K Christopher McMains; Richard R Orlandi
Journal:  Int Forum Allergy Rhinol       Date:  2014-01-02       Impact factor: 3.858

5.  European Position Paper on Rhinosinusitis and Nasal Polyps 2012.

Authors:  Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald
Journal:  Rhinol Suppl       Date:  2012-03

6.  Topical Drug Delivery for Chronic Rhinosinusitis.

Authors:  Jonathan Liang; Andrew P Lane
Journal:  Curr Otorhinolaryngol Rep       Date:  2012-12-27

7.  Apical oxidative hyaluronan degradation stimulates airway ciliary beating via RHAMM and RON.

Authors:  Dahis Manzanares; Maria-Elena Monzon; Rashmin C Savani; Matthias Salathe
Journal:  Am J Respir Cell Mol Biol       Date:  2007-03-29       Impact factor: 6.914

8.  Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin.

Authors:  T Ahmed; J Garrigo; I Danta
Journal:  N Engl J Med       Date:  1993-07-08       Impact factor: 91.245

9.  Novel sulfated polysaccharides disrupt cathelicidins, inhibit RAGE and reduce cutaneous inflammation in a mouse model of rosacea.

Authors:  Jianxing Zhang; Xiaoyu Xu; Narayanam V Rao; Brian Argyle; Lindsi McCoard; William J Rusho; Thomas P Kennedy; Glenn D Prestwich; Gerald Krueger
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

Review 10.  Hyaluronan, a crucial regulator of inflammation.

Authors:  Aaron C Petrey; Carol A de la Motte
Journal:  Front Immunol       Date:  2014-03-11       Impact factor: 7.561

View more
  8 in total

1.  Temperature-responsive silk-elastinlike protein polymer enhancement of intravesical drug delivery of a therapeutic glycosaminoglycan for treatment of interstitial cystitis/painful bladder syndrome.

Authors:  M Martin Jensen; Wanjian Jia; Austin J Schults; Kyle J Isaacson; Douglas Steinhauff; Bryant Green; B Zachary; Joseph Cappello; Hamidreza Ghandehari; Siam Oottamasathien
Journal:  Biomaterials       Date:  2019-06-20       Impact factor: 12.479

Review 2.  Targeting of Glycosaminoglycans in Genetic and Inflammatory Airway Disease.

Authors:  Robin Caird; Michael Williamson; Azeez Yusuf; Debananda Gogoi; Michelle Casey; Noel G McElvaney; Emer P Reeves
Journal:  Int J Mol Sci       Date:  2022-06-08       Impact factor: 6.208

Review 3.  Neutrophil Elastase and Chronic Lung Disease.

Authors:  Judith A Voynow; Meagan Shinbashi
Journal:  Biomolecules       Date:  2021-07-21

4.  Polysulfated Hyaluronan GlycoMira-1111 Inhibits Elastase and Improves Rheology in Cystic Fibrosis Sputum.

Authors:  Apparao B Kummarapurugu; Shuo Zheng; Abigail Pulsipher; Justin R Savage; Jonathan Ma; Bruce K Rubin; Thomas P Kennedy; Judith A Voynow
Journal:  Am J Respir Cell Mol Biol       Date:  2021-02       Impact factor: 6.914

5.  LL-37 causes cell death of human nasal epithelial cells, which is inhibited with a synthetic glycosaminoglycan.

Authors:  Andrew J Thomas; Abigail Pulsipher; Brock M Davis; Jeremiah A Alt
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

Review 6.  Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease.

Authors:  Judith A Voynow; Shuo Zheng; Apparao B Kummarapurugu
Journal:  Front Pharmacol       Date:  2020-07-08       Impact factor: 5.810

7.  A synthetic glycosaminoglycan reduces sinonasal inflammation in a murine model of chronic rhinosinusitis.

Authors:  Jeremiah A Alt; Won Yong Lee; Brock M Davis; Justin R Savage; Thomas P Kennedy; Glenn D Prestwich; Abigail Pulsipher
Journal:  PLoS One       Date:  2018-09-25       Impact factor: 3.240

8.  An Oligomeric Sulfated Hyaluronan and Silk-Elastinlike Polymer Combination Protects against Murine Radiation Induced Proctitis.

Authors:  Douglas Steinhauff; Mark Martin Jensen; Ethan Griswold; Jolanta Jedrzkiewicz; Joseph Cappello; Siam Oottamasathien; Hamidreza Ghandehari
Journal:  Pharmaceutics       Date:  2022-01-12       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.